Collaboration Credited for Sustainable Packaging Solution (PRWeb February 01, 2012) Read the full story at http://www.prweb.com/releases/2012/2/prweb9141045.htm

In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. Two new studies are published today on these drugs. One published by The Lancet Oncology, showing lapatinib to be less beneficial than trastuzumab for single-agent therapy ...